## BMJ Open Diabetes Research & Care

# Weight trajectories since birth, current body composition and metabolic traits in young, normal-weight Japanese women with high percentage body fat

Satomi Minato-Inokawa,<sup>1,2,3</sup> Asami Hashiguchi,<sup>4</sup> Mari Honda,<sup>5,6</sup> Ayaka Tsuboi-Kaji,<sup>1,7</sup> Mika Takeuchi,<sup>1</sup> Kaori Kitaoka,<sup>1,8</sup> Miki Kurata,<sup>1,4</sup> Bin Wu,<sup>5,9</sup> Tsutomu Kazumi (1),<sup>1,5,10</sup> Keisuke Fukuo<sup>1,4,5</sup>

#### ABSTRACT

**Introduction** We tested whether normal-weight obesity might be associated with weight trajectories, body composition and metabolic traits.

**Research design and methods** Body size trajectory since birth, body composition at age 20 years and metabolic traits were compared cross-sectionally among normal-weight Japanese women with low (<25.0%, n=67), normal (25.0–34.9%, n=160) and high ( $\geq$ 35.0 %, n=24) percentage body fat. Multivariate logistic regression analyses were used to identify most important determinants of normal-weight obesity (high percentage body fat).

Results Fasting glucose averaged <84 mg/dL, homeostasis model assessment-insulin resistance <1.4 and triglyceride <70 mg/dL and did not differ among three groups. However, waist and trunk/leg fat ratio were higher, and weight-adjusted skeletal muscle mass was lower in normal-weight obesity. Serum and LDL cholesterol, apolipoprotein B (ApoB) and high-sensitivity C reactive protein were higher, and apolipoprotein A1 was lower in normal-weight obesity compared with the other two groups, whereas HDL cholesterol did not differ. Weight gain from birth to age 12 years was higher in normal-weight obesity. In multivariate logistic regression analyses, weight gain until 12 years (OR: 1.17,95% CI 1.02 to 1.34, p=0.02), ApoB (OR: 1.15, 95% CI 1.06 to 1.24, p<0.001) and weight-adjusted skeletal muscle mass (OR: 0.22, 95% CI 0.10 to 0.49, p<0.001) were associated with normal-weight obesity independently of trunk/leg fat ratio. high-sensitivity C reactive protein and apolipoprotein A1. Conclusions Normal-weight obesity may be associated with early childhood growth, lower skeletal muscle mass and higher serum ApoB in young Japanese women through mechanisms unrelated to abdominal adiposity, inflammation and insulin resistance.

#### INTRODUCTION

It is well known that subjects with normal weight (defined as a body mass index (BMI) of  $18.5-24.9 \, \text{kg/m}^2$ ) have a lower risk for cardiometabolic diseases and all-cause mortality compared with overweight and obese subjects.<sup>1</sup><sup>2</sup> As BMI does not

#### WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Normal-weight obesity has been shown to be associated with high triglyceride and low high-density lipoprotein cholesterol. However, studies evaluating associations with apolipoproteins and growth during childhood are limited.

#### WHAT THIS STUDY ADDS

- ⇒ Normal-weight obesity was associated with weight gain from birth until 12 years, lower skeletal muscle mass and higher serum apolipoprotein B in young Japanese women.
- ⇒ Theses associations were independent of trunk/leg fat ratio, insulin resistance and high-sensitivity C reactive protein.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Normal-weight obesity may be associated with early childhood growth and increased cardiometabolic risk through mechanisms unrelated to abdominal adiposity, insulin resistance and inflammation in young Japanese women. Our study highlights rapid childhood growth as a risk factor for normal-weight obesity, which is associated with cardiometabolic morbidity and mortality.

differentiate fat-free mass from adipose tissue, an individual with normal weight may have low, appropriate or excess fat. Normalweight obesity is characterized by the presence of high body fat despite having a normal BMI and is associated with cardiometabolic morbidity and mortality.<sup>3</sup> Epidemiological and experimental data indicate that nutritional or environmental stressors during early development can induce long-term adaptations that increase risk of diabetes and cardiovascular disease.<sup>4</sup> Altered body composition characterized by increased fat mass and reduced muscle mass is a common phenotype.<sup>5</sup> In addition, current evidence suggests

Hashiguchi A, Honda M, *et al.* Weight trajectories since birth, current body composition and metabolic traits in young, normal-weight Japanese women with high percentage body fat. *BMJ Open Diab Res Care* 2022;**10**:e003045. doi:10.1136/ bmjdrc-2022-003045

To cite: Minato-Inokawa S,

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/bmjdrc-2022-003045).

Received 13 July 2022 Accepted 12 December 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

#### **Correspondence to**

Dr Tsutomu Kazumi; kazumi@mukogawa-u.ac.jp that growth and body weight trajectories in infancy and childhood are useful indicators of later obesity and type 2 diabetes.<sup>6</sup> As far as we know, however, studies are missing in people with normal-weight obesity.

Most of triglycerides and cholesterol in the circulation are carried in very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particles, respectively, both of which contain one molecule of apolipoprotein B (ApoB). ApoB is a single index that quantitates the atherogenic risk due to the ApoB-containing lipoprotein particles.<sup>7</sup> Although triglycerides and LDL cholesterol are both risk factors of cardiovascular disease, a study indicates that the clinical benefit of lowering triglyceride and LDL cholesterol levels may be proportional to the absolute change in ApoB.<sup>8</sup> Although many studies reported associations of normal-weight obesity with cardiometabolic abnormalities including high triglyceride and LDL cholesterol,<sup>3</sup> studies are limited on the association with ApoB.<sup>910</sup> Age, sex and race/ethnicities may be related to normal-weight obesity.<sup>3</sup> We, therefore, studied whether normal-weight obesity may be associated with body weight trajectories since birth to childhood, current body composition, dietary intake and a broad range of cardiometabolic risks including ApoB in young Japanese women in the present study.

#### **Subjects and methods**

We reanalyzed cross-sectionally 251 normal weight (BMI:  $18.5-24.9 \text{ kg/m}^2$ ) women, whose age and BMI averaged 20.6 years and  $20.6 \text{ kg/m}^2$ , respectively, among 307 young Japanese women whose details were reported previously,<sup>11</sup> from which 56 underweight (BMI  $<18.5 \text{ kg/m}^2$ ) and overweight (BMI:  $25.0-29.9 \text{ kg/m}^2$ ) women were excluded. They were students of Department of Food Sciences and Nutrition, Mukogawa Women's University and were recruited as volunteers. Among 251 women, 181 and 166 women provided data on weight trajectory and dietary intake, respectively. Women with clinically diagnosed acute or chronic inflammatory diseases, endocrine, cardiovascular, hepatic, renal diseases, hormonal contraception, unusual dietary habits were excluded from the study. This research followed the tenets of the Declaration of Helsinki.

Weight at birth, and height and weight at age 12 and 15 years were obtained either through maternal health check notes or child health notebook records (issued by each municipal office).

After a 12-hours overnight fast, participants underwent blood sampling, measurement of anthropometric indices, blood pressure and body composition as previously described.<sup>10-14</sup> Blood pressure was measured using an automated sphygmomanometer (BP-203RV II, Colin, Tokyo, Japan) after participants were seated at least for 5 min. Plasma glucose, serum insulin, triglycerides, cholesterol, high-density lipoprotein (HDL) cholesterol, free fatty acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT),  $\gamma$ -glutamyl transpeptidase (GGT), HbA1c and high-sensitivity C reactive protein (hsCRP) were measured as previously reported.<sup>10-14</sup> LDL cholesterol was calculated using the Friedewald's formula. Adipose tissue-insulin resistance index (AT-IR) and homeostasis model assessment-insulin resistance (HOMA-IR) were calculated as previously reported.<sup>1415</sup>

Whole-body dual-energy X-ray absorptiometry (DXA) (Hologic QDR-2000 software version 7.20D, Waltham, Massachusetts, USA) was used to measure lean tissue mass, fat mass and bone mineral mass for arms, legs (lower body), trunk and the total body.<sup>12</sup> General adiposity was assessed using BMI, percentage body fat (%BF) and fat mass index (FMI), the last of which was calculated as body fat mass in kg divided by height in meter squared. Waist circumference, percentage trunk fat and the ratio of trunk to leg fat<sup>16</sup> were considered as markers of abdominal fat accumulation. Muscle characteristics were evaluated by relative appendicular skeletal muscle mass (ASM) as percentage of body mass (%ASM) and absolute ASM index (ASM/height<sup>2</sup> in kg/m<sup>2</sup>). %ASM is suggested to be a better predictor of insulin resistance and diabetes risk than ASM or ASM index.<sup>17</sup>

There are no clearly established cut points of %BF for normal-weight obesity. A study employing DXA showed that %BF for a BMI of 18.5 and 25.0 kg/m<sup>2</sup> corresponded to 25.0% and 35.0%, respectively, in Japanese women aged 20–39 years.<sup>18</sup> Similar results were obtained in our analyses in the entire 307 young Japanese women (data not shown). Accordingly, high %BF, that is, normalweight obesity, was defined by  $\geq$ 35.0% (n=24, 9.6%). Because a substantial number of normal-weight women (n=67, 26.7%) had %BF <25.0%, they were considered as having low %BF and used as an internal reference. A %BF of 25.0–34.9% was defined as normal (n=160, 63.7%).

Dietary intake of the previous month was assessed using the self-administered diet history questionnaire.<sup>19</sup> This has been widely used throughout Japan, and its validity with respect to commonly studied nutrition factors has been confirmed.

Data were presented as mean±SD unless otherwise stated. Due to deviation from normal distribution, hsCRP were logarithmically transformed for analyses. Differences among three groups were analyzed by analysis of variance and then Bonferroni's multiple comparison procedure. Stepwise multivariate logistic regression analyses were used to identify most important determinants of normal-weight obesity. Independent variables included were variables that showed significant difference among three groups. A two-tailed p<0.05 was considered statistically significant. All calculations were performed with SPSS system V.23.0 (SPSS Inc).

#### RESULTS

Of 251 normal-weight Japanese women, nobody had metabolic syndrome, and 239 women had none of metabolic syndrome components. There were 11 women who had a single component and a single woman with normal-weight obesity who had two components.

Table 1	Neight trajectories since birth and current body composition in young, normal-weight Japanese women wit	h low,
normal a	d high percentage body fat	

	Percentage body	Percentage body fat		
	Low	Normal	High	
	n=67	n=160	n=24	*
Weight (g or kg) at birth	3166 ± 409	3211 ± 381	3178 ± 401	
At 12 years	41.0 ± 5.2	$44.1 \pm 6.0$	$45.2 \pm 9.2$	†‡
At 15 years	47.1 ± 4.3	$49.8 \pm 5.6$	$53.3 \pm 6.4$	†‡§
At 20 years	$48.8 \pm 3.8$	$52.5 \pm 4.5$	$56.9 \pm 4.6$	†‡§
∆Weight <sub>0-12</sub> (kg)	37.8 ± 5.1	$40.9 \pm 5.9$	42.0 ± 9.1	†‡
Height (cm) at 12 years	$148.8 \pm 6.2$	151.9 ± 5.5	150.7 ± 9.0	†
At 15 years	$155.4 \pm 5.4$	$157.6 \pm 4.6$	157.7 ± 5.3	†
At 20 years	$158.3 \pm 5.4$	159.1 ± 4.8	$159.4 \pm 4.9$	
BMI (kg/m²) at 12 years	$18.4 \pm 1.8$	19.1 ± 2.0	$19.7 \pm 2.7$	
At 15 years	19.5 ± 1.3	20.0 ± 1.8	$21.4 \pm 2.0$	‡
At 20 years	$19.5 \pm 0.8$	20.7 ± 1.3	$22.4 \pm 1.6$	†‡§
Waist (cm)	68.1 ± 4.1	$72.2 \pm 4.4$	$78.6 \pm 3.7$	†‡§
Percentage body fat (%)	22.9 ± 1.9	29.3 ± 2.7	36.7 ± 1.5	†‡§
Percentage trunk fat (%)	23.1 ± 2.4	$30.4 \pm 3.6$	38.6 ± 2.2	†‡§
%ASM (%)	30.6 ± 1.4	28.4 ± 1.6	25.5 ± 1.4	†‡§
Trunk/leg fat ratio	1.19 ± 0.20	1.28 ± 0.25	$1.36 \pm 0.23$	†‡
ASMI (kg/m <sup>2</sup> )	$6.0 \pm 0.4$	$5.9 \pm 0.5$	5.7 ± 0.5	
FMI (kg/m <sup>2</sup> )	$4.4 \pm 0.5$	$6.0 \pm 0.8$	8.1 ± 0.8	†‡§

Mean±SD  $\Delta$ Weight<sub>0-12</sub>: weight gain from birth to age 12 years.

\*P<0.05 or less by Bonferroni's multiple comparison procedure.

+Low versu normal.

‡Low versus high.

§Normal versus high.

ASM, appendicular skeletal muscle mass; BMI, body mass index; FMI, fat mass index.

Although BMI and waist increased in a stepwise fashion from the low to high %BF, women with normal-weight obesity had a mean BMI of 22.4 kg/m<sup>2</sup>, waist 78.6 cm and ALT 13 U/L (tables 1 and 2). Fasting glucose averaged <84 mg/dL, HbA1c <5.3% and triglyceride <70 mg/dL and did not differ among three groups (table 2).

There was no difference in birth weight (table 1). However, weight at 12, 15 and 20 years was higher in normal and high compared with low %BF group. Therefore, weight gain until 12 years was higher in women with normal and high compared with low %BF. There were no or modest differences in height. Percentage trunk fat, trunk/leg fat ratio and fat mass index increased and %ASM decreased in a stepwise fashion from the low through the high %BF although there was no difference in ASM index (table 1 and figure 1).

Despite remarkable differences in trunk/leg fat ratio, %BF and %ASM, there was no difference in HOMA-IR, AT-IR and adiponectin (table 2). Serum and LDL cholesterol, ApoB and hsCRP were higher and ApoA1 was lower in normal-weight obesity compared with the other two groups whereas HDL cholesterol did not differ (figures 1 and 2). There was no difference in daily energy intake and macronutrients among normal-weight women with low, normal and high %BF (online supplemental table 1).

It is noteworthy that normal-weight obese women were comparable to overweight women whose BMI averaged 26.6 kg/m2<sup>11</sup> in % BF, %ASM, serum leptin, log hsCRP, ApoB and LDL cholesterol (figures 1 and 2). ApoAl concentrations were lower in normal-weight obese compared with overweight women (figure 2). Similarly, normal-weight women with low %BF were comparable with underweight women whose BMI averaged 17.5 kg/m2<sup>11</sup> in % BF (22.9 v. 21.5 %) and %ASM (30.6 v. 30.8 %).

In multivariate logistic regression analyses (table 3), weight gain until 12 years, ApoB and %ASM were associated with normal-weight obesity independently of trunk/ leg fat ratio, ApoA1 and hsCRP.

When Asian-specific cut-offs of BMI definitions for normal weight  $(18.5-22.9 \text{ kg/m}^2)$  was applied (online supplemental table 2), only 13 women (5.6 %) had high %BF among 232 normal-weight women. However, results were similar to those in tables 1 and 2: higher weight gain from birth to age 12 years, waist, % trunk ratio, serum 
 Table 2
 Cardiometabolic risk factors in young, normal-weight Japanese women with low, normal and high percentage body fat

	Percentage boo	Percentage body fat		
	Low	Normal	High	
	n=67	n=160	n=24	*
Fasting glucose (mg/dL)	82 ± 7	83 ± 7	83 ± 5	
HbA1c (%)	$5.2 \pm 0.2$	$5.2 \pm 0.2$	$5.1 \pm 0.3$	
FFA (mEq/L)	0.55 ± 0.17	$0.57 \pm 0.24$	$0.5 \pm 0.21$	
Fasting insulin (µU/mL)	$5.3 \pm 2.5$	$6.3 \pm 3.6$	$6.6 \pm 3.5$	
HOMA-IR	$1.1 \pm 0.6$	1.3 ± 0.8	$1.3 \pm 0.8$	
AT-IR	2.9 ± 1.9	3.7 ± 3.3	2.7 ± 1.5	
Triglyceride (mg/dL)	52 ± 23	57 ± 25	65 ± 32	
Cholesterol (mg/dL)	177 ± 25	182 ± 26	199 ± 28	†‡
HDL cholesterol (mg/dL)	76 ± 12	75 ± 14	70 ± 15	†‡
LDL cholesterol (mg/dL)	91 ± 20	96 ± 21	117 ± 30	†‡
Apolipoprotein A1 (mg/dL)	165 ± 18	165 ± 20	154 ± 20	†‡
Apolipoprotein B (mg/dL)	66 ± 12	70 ± 14	84 ± 19	†‡
Leptin (ng/mL)	5.8 ± 1.7	9.1 ± 3	13.2 ± 5	§†‡
Adiponectin (µg/mL)	11.6 ± 3.7	11.4 ± 4.3	10.9 ± 4	
hsCRP (µg/dL)	21 ± 64	27 ± 63	64 ± 124	†‡
log hsCRP	0.91 ± 0.42	$1.06 \pm 0.48$	1.37 ± 0.57	†‡
AST (U/L)	17 ± 3.1	17.4 ± 4.6	19.2 ± 10.3	
ALT (U/L)	$12.5 \pm 4.4$	13 ± 7.2	12.9 ± 11.3	
GGT (U/L)	$14.3 \pm 4.4$	13.4 ± 3.6	16.4 ± 10.2	
Systolic BP (mm Hg)	104 ± 8	106 ± 10	108 ± 11	
Diastolic BP (mm Hg)	60 ± 7	61 ± 7	62 ± 7	

Mean±SD AT-IR; adipose tissue-insulin resistance.

\*P<0.05 or less by Bonferroni's multiple comparison procedure.

+Low versus high.

‡Normal versus high.

§Low versus normal.


ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; FFA, free fatty acid; GGT, γ-glutamyltranspeptidase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment-insulin resistance; hsCRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein.

and LDL cholesterol, ApoB and hsCRP and lower %ASM in women with high %BF.

#### DISCUSSION

The current study confirmed associations of normalweight obesity with abdominal fat accumulation and low muscle mass as previously reviewed<sup>3</sup> and demonstrated that normal-weight obesity was associated with early childhood growth and higher serum ApoB in young, normal-weight Japanese women. These associations were independent of trunk/leg fat ratio, sophisticated measures of abdominal fat accumulation and hsCRP, a marker of chronic systemic low-grade inflammation. It is noteworthy that fasting insulin, HOMA-IR and AT-IR did not differ among three groups of women despite remarkable differences in %BF, trunk/leg fat ratio and percentage trunk fat, the last of which has been shown to be associated with increased risk of cardiovascular disease in postmenopausal women with normal BMI.<sup>20</sup> In addition, waist and ALT averaged 78.6 cm and 13 U/L, respectively, in women with normal-weight obesity, suggesting a minimum abdominal and hepatic fat accumulation, respectively.


Multiple studies showed associations of normal-weight obesity with dyslipidemia including high triglyceride and LDL cholesterol and low HDL cholesterol in adolescents and adults.<sup>3 21</sup> However, we found only two studies on the association with ApoB.<sup>9 10</sup> Swedish middle-aged people with normal-weight obesity had higher waist and ApoB compared with the normal weight leanness group, whereas ApoA1 did not differ.<sup>9</sup> The second study showed associations of ApoB with %BF and HOMA-IR in young India subjects with normal-weight obesity.<sup>10</sup> In the present study, ApoB not ApoA1 showed associations



**Figure 1** Percentage body fat (% body fat), weightadjusted appendicular skeletal muscle mass (% ASM), serum leptin and high-sensitivity C reactive protein (logarithmically transformed, log hsCRP) in young, normal-weight Japanese women with the low (green squares, n=67), normal (blue squares, n=160) and high percentage body fat (yellow squares, n=24), the last of which represent normal-weight obesity. Red squares are results of 14 overweight women.<sup>11</sup> Mean±SD means not sharing common letter are significantly different with each other at p<0.05 or less by Bonferroni's multiple comparison procedure. #P<0.05 versus normalweight obesity. hsCRP, high-sensitivity C reactive protein.

with normal-weight obesity independent of abdominal adiposity and insulin resistance although ApoA1 was lower in normal weight obese compared with overweight women.

Fat storage increase in response to positive energy balance and/or disturbances in pathways of lipolysis in adipose tissue.<sup>22</sup> A reduced catecholamine-induced lipolysis may contribute to the development and maintenance of increased adipose tissue stores. A number of studies suggest that there is lipolytic resistance to



**Figure 2** Serum apolipoprotein A1 and B (ApoA1 and ApoB, respectively), high-density and low-density lipoprotein cholesterol (HDL-C and LDL-C, respectively) in young, normal-weight Japanese women with the low (green squares, n=67), normal (blue squares, n=160) and high percentage body fat (yellow squares, n=24), the last of which represent normal-weight obesity. Red squares are results of 14 overweight women.<sup>11</sup> Mean±SD means not sharing common letter are significantly different with each other at p<0.05 or less by Bonferroni's multiple comparison procedure. #P<0.05 versus normal-weight obesity.

 
 Table 3
 Multivariable logistic regression analyses for normal-weight obesity

		95% CI		
	OR	Lower	Upper	P values
%ASM	0.22	0.10	0.49	<0.001
Apolipoprotein B	1.15	1.06	1.24	<0.001
$\Delta Weight_{0-12}$	1.17	1.02	1.34	0.027
log hsCRP	5.3	0.9	30.2	0.059

Other independent variables included: trunk/leg fat ratio and apolipoprotein A1.

ASM, appendicular skeletal muscle mass; HOMA-IR, homeostasis model assessment-insulin resistance; hsCRP, high-sensitivity C reactive protein.

catecholamines in subcutaneous adipose tissue in obese subjects.<sup>22</sup> Skogsberg *et al* studied the effects of ApoBcontaining lipoproteins on catecholamine-induced lipolysis in adipocytes from subcutaneous fat cells of obese men, fat pads from mice with plasma lipoproteins containing high or intermediate levels of ApoB100 or no ApoB100, primary cultured adipocytes and 3T3-L1 cells.<sup>23</sup> They showed that the binding of ApoB in LDL particles to LDL receptors on cell membrane of adipocytes inhibits intracellular noradrenaline-induced lipolysis in adipocytes. We speculate that because daily energy intake did not differ among three groups of women, decreased lipolysis associated with higher ApoB may be related to higher %BF in normal-weight Japanese women in the present study. We found associations of ApoB not only with %BF and FMI but with leptin, adiponectin (inversely) and hence leptin/adiponectin ratio, the last of which represents a marker of compromised adipocyte function,<sup>24</sup> in non-obese young female university students and their middle-aged parents (paper in preparation).

Elevated ApoB may be a component of the metabolic syndrome,<sup>25</sup> and higher ApoB in VLDL and LDL particles have been reported to occur in the early phase of insulin resistant women with abdominal obesity who had normal fasting glucose and triglyceride levels.<sup>26</sup> A recent Mendelian randomization study showed that genetically higher body fat percentage had a causal effect on ApoB.<sup>27</sup> Higher serum ApoB was explained by increased synthesis of ApoB and large VLDI by the liver and impaired lipolysis of VLDL and increased residence time in the circulation, both of which resulted from increased visceral adipose tissue and insulin resistance.<sup>27</sup> However, association between ApoB and normal-weight obesity in young women was independent of abdominal fat accumulation and insulin resistance.

Nutritional or environmental stressors during fetal life and infancy may be associated with increased fat mass and reduced muscle mass in later life,<sup>5</sup> a phenotype seen in women with normal-weight obesity in the present study. However, birth weight was not associated with normal-weight obesity in Japanese women. Instead, early childhood growth (weight gain since birth to age 12

#### Cardiovascular and metabolic risk

years) was associated with normal-weight obesity in the present study. This may be in line with the study by Zhang *et al*,<sup>28</sup> who found strong associations between the metabolic markers measured at 11.5 years of age and three growth measures (ages 3–12 months, ages 12 months-6.5 years and ages 6.5–11.5 years), with the largest magnitudes being observed during the latest age period (ages 6.5–11.5 years). To the best of our knowledge, the current study may be the first to demonstrate an association of childhood growth with normal-weight obesity.

The accurate and reliable measures of general and central fat accumulation by DXA are the strength of the present study. There are several limitations of this study including the cross-sectional design, relatively small sample size and a single measurement of biochemical variables. The notion that ApoB inhibits intracellular noradrenaline-induced lipolysis in adipocytes is presently supported by a single publication only.<sup>23</sup> However, multiple studies reported the relation of elevated ApoB to white adipose tissue dysfunction.<sup>29–33</sup> The study population included only female university students. However, this also might be considered as a strength since it eliminates potential confounding factors.<sup>12</sup> For example, more than 90% of grade 1 students are 18 years old. This may decrease the interference of age and environmental factors, including smoking, alcohol, educational and socioeconomic status. Furthermore, in almost all students, almost all school expenses were covered by parents, suggesting that socioeconomic status appears to be less heterogeneous among parents who fed participants of the present study. We did not assess family history of obesity and current exercise habits. However, participants had 9367±1971 steps/day (mean±SD of 77 participants, who used a pedometer for 14 days, and the mean steps a day were calculated for each participant), although they were not engaged in any regular sport activity. We did not measure sex hormones. Statistical power and sample size were not calculated. As participants were young Japanese women, the results may not be generalized to other gender, age populations, races or ethnicities.

In conclusion, normal-weight obesity may be associated with early childhood growth, lower skeletal muscle mass and higher serum ApoB in young Japanese women through mechanisms unrelated to abdominal adiposity, insulin resistance and inflammation. Our study highlights rapid childhood growth as a risk factor for normalweight obesity, which is associated with cardiometabolic morbidity and mortality. Prospective follow-up studies are needed to see if these phenotypes predict clinical outcomes (ie, development of diabetes or cardiovascular disease).

#### **Author affiliations**

<sup>1</sup>Eiyo kagakukenkyujo, Mukogawa Joshi Daigaku, Nishinomiya, Japan <sup>2</sup>Laboratory of Community Health and Nutrition, Department of Bioscience, Graduate School of Agriculture, Ehime University, Matsuyama, Ehime, Japan <sup>3</sup>Center for the Promotion of Interdisciplinary Education and Research, Kyoto University, Kyoto, Japan <sup>4</sup>Department of Food Sciences and Nutrition, Mukogawa Joshi Daigaku, Nishinomiya, Japan

<sup>5</sup>Open Research Center for Studying of Lifestyle-Related Diseases, Mukogawa Joshi Daigaku, Nishinomiya, Hyogo, Japan

<sup>6</sup>Department of Health, Sports, and Nutrition, Faculty of Health and Welfare, Kobe Women's University, Kobe, Hyogo, Japan

<sup>7</sup>Department of Nutrition, Osaka City Juso Hospital, Osaka, Japan

<sup>8</sup>Department of Advanced Epidemiology, Noncommunicable Disease (NCD) Epidemiology Research Center, Shiga University of Medical Science, Otsu, Shiga, Japan

<sup>9</sup>First Affiliated Hospital of Kunming Medical University, Kunming, China <sup>10</sup>Department of Medicine, Kohan Kakogawa Hospital, Kakogawa, Hyogo, Japan

Acknowledgements We would like to thank all participants for their dedicated and conscientious collaboration.

**Contributors** SM-I, AH, MH and AT-K collected data and prepared figures. MT, KK, MK and BW analyzed data and prepared tables. TK wrote the manuscript, and KF reviewed and edited it. All authors approved the final version of the manuscript to be published. TK supervised the study, had full access to all thedata in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the Ethics Committees of Mukogawa Women's University (No. 07-28 on 19/02/2008). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### ORCID iD

Tsutomu Kazumi http://orcid.org/0000-0002-8855-9268

#### REFERENCES

- Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju S, ShN B, *et al.* Body-mass index and all-cause mortality: individualparticipant-data meta-analysis of 239 prospective studies in four continents. *Lancet* 2016;388:776–86.
- 2 Bhaskaran K, Dos-Santos-Silva I, Leon DA, et al. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3-6 million adults in the UK. Lancet Diabetes Endocrinol 2018;6:944–53.
- 3 Wijayatunga NN, Dhurandhar EJ. Normal weight obesity and unaddressed cardiometabolic health risk-a narrative review. Int J Obes 2021;45:2141–55.
- 4 Gluckman PD, Hanson MA, Cooper C, et al. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008;359:61–73.
- 5 Isganaitis E. Developmental programming of body composition: update on evidence and mechanisms. *Curr Diab Rep* 2019;19:60.
- 6 Gingras V, Hivert M-F, Oken E. Early-life exposures and risk of diabetes mellitus and obesity. *Curr Diab Rep* 2018;18:89.

## 6

#### Cardiovascular and metabolic risk

- 7 Sniderman AD, Thanassoulis G, Glavinovic T, *et al*. Apolipoprotein B particles and cardiovascular disease: a narrative review. *JAMA Cardiol* 2019;4:1287–95.
- 8 Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceridelowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA 2019;321:364–73.
- 9 Berg C, Strandhagen E, Mehlig K, et al. Normal weight adiposity in a Swedish population: how well is cardiovascular risk associated with excess body fat captured by BMI? Obes Sci Pract 2015;1:50–8.
- 10 Manapurath RM, Hadaye R, Gadapani B. Normal weight obesity: role of apoB and insulin sensitivity in predicting future cardiovascular risk. *Int J Prev Med* 2022;13:31.
- 11 Takeuchi M, Honda M, Tsuboi A, et al. Weight trajectory since birth, current body composition, dietary intake, and glucose tolerance in young underweight Japanese women. Womens Health Rep 2022;3:215–21.
- 12 Tanaka M, Yoshida T, Bin W, et al. FTO, abdominal adiposity, fasting hyperglycemia associated with elevated HbA1c in Japanese middleaged women. J Atheroscler Thromb 2012;19:633–42.
- 13 Kitaoka K, Takeuchi M, Tsuboi A, et al. Increased adipose and muscle insulin sensitivity without changes in serum adiponectin in young female collegiate athletes. *Metab Syndr Relat Disord* 2017;15:246–51.
- 14 Kitaoka K, Tsuboi A, Minato-Inokawa S, et al. Determinants and correlates of adipose tissue insulin resistance index in Japanese women without diabetes and obesity. *BMJ Open Diabetes Res Care* 2020;8:e001686.
- 15 Matthews DR, Hosker JP, Rudenski AS, *et al.* Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–9.
- 16 Lim Ú, Turner SD, Franke AA, et al. Predicting total, abdominal, visceral and hepatic adiposity with circulating biomarkers in caucasian and Japanese American women. PLoS One 2012;7:e43502.
- 17 Bijlsma AY, Meskers CGM, van Heemst D, et al. Diagnostic criteria for sarcopenia relate differently to insulin resistance. Age 2013;35:2367–75.
- 18 Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000;72:694–701.
- 19 Okubo H, Sasaki S, Rafamantanantsoa HH, et al. Validation of self-reported energy intake by a self-administered diet history questionnaire using the doubly labeled water method in 140 Japanese adults. Eur J Clin Nutr 2008;62:1343–50.

- 20 Chen G-C, Arthur R, Iyengar NM, et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. *Eur Heart J* 2019;40:2849–55.
- 21 Cota BC, Suhett LG, Leite NN, et al. Cardiometabolic risk and health behaviours in adolescents with normal-weight obesity: a systematic review. Public Health Nutr 2021;24:870–81.
- 22 Jocken JWE, Blaak EE. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. *Physiol Behav* 2008;94:219–30.
- 23 Skogsberg J, Dicker A, Rydén M, et al. ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes. PLoS One 2008;3:e3771.
- 24 Finucane FM, Luan J, Wareham NJ, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in nondiabetic individuals. *Diabetologia* 2009;52:2345–9.
- 25 Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. *Curr Opin Lipidol* 2007;18:633–7.
- 26 Pont F, Duvillard L, Florentin E, et al. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol 2002;22:1726–32.
- 27 Webb RJ, Mazidi M, Lip GYH, *et al.* The role of adiposity, diet and inflammation on the discordance between LDL-C and apolipoprotein B. *Nutr Metab Cardiovasc Dis* 2022;32:605–15.
- 28 Zhang X, Martin RM, Oken E, et al. Growth during infancy and early childhood and its association with metabolic risk biomarkers at 11.5 years of age. Am J Epidemiol 2020;189:286–93.
- 29 Sniderman AD, Cianflone K, Frayn K. The pathogenetic role of impaired fatty acid trapping by adipocytes in generating the pleiotropic features of hyperapoB. *Diabetologia* 1997;40 Suppl 2:S152–4.
- 30 Hoffstedt J, Förster D, Löfgren P. Impaired subcutaneous adipocyte lipogenesis is associated with systemic insulin resistance and increased apolipoprotein B/AI ratio in men and women. *J Intern Med* 2007;262:131–9.
- 31 Bissonnette S, Salem H, Wassef H, et al. Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue. J Lipid Res 2013;54:1466–76.
- 32 Lamantia V, Bissonnette S, Wassef H, et al. ApoB-lipoproteins and dysfunctional white adipose tissue: relation to risk factors for type 2 diabetes in humans. J Clin Lipidol 2017;11:34–45.
- 33 Faraj M. Ldl, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue. J Biomed Res 2020;34:251–9.